Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hls Therapeutics Inc (HLS.TO)

Hls Therapeutics Inc (HLS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Hls Therapeutics Inc 10 Carlson Court Suite 701 Etobicoke ON M9W 6L2 CAN

https://www.hlstherapeutics.com P: 647-495-9000 F: 416-213-0045

Sector:

Medical

Description:

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.

Key Statistics

Overview:

Market Capitalization, $K 147,612
Shares Outstanding, K 31,274
% of Institutional Shareholders 0.37%

Financials:

Annual Sales, $ 56,619 K
Annual Net Income, $ -19,655 K
Last Quarter Sales, $ 13,511 K
Last Quarter Net Income, $ -3,918 K

Growth:

1-Year Return 18.30%
3-Year Return -50.83%
5-Year Return -71.17%
5-Year Revenue Growth 0.89%

Per-Share Information:

Most Recent Earnings -0.12 on 11/13/25
Next Earnings Date 03/12/26
Earnings Per Share ttm -0.45
EPS Growth vs. Prev Year -34.78%
Annual Dividend & Yield (Fwd) 0.20 (0.00%)
Most Recent Dividend 0.050 on 04/27/23
Next Ex-Dividends Date 04/27/23
Dividend Payable Date 06/15/23
Dividend Payout Ratio 0.00%

HLS.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -20.02%
Return-on-Assets % -9.05%
Profit Margin % -34.71%
Debt/Equity 0.86
Price/Sales 1.92
Price/Book 1.72
Book Value/Share 2.74
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar